Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pulmatrix, Inc. (PULM)
USD1.57
-0.05 (-3.09%)
US NASDAQ Healthcare Biotechnology
Address
99 Hayden Avenue 2421
Lexington, MA, US
Lexington, MA, US
CEO
Peter Ludlum
Website
pulmatrix.com
IPO
2014-03-21
CIK 1574235 ISIN US74584P3010
Description
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| RetinalGenix Technologies Inc. | RTGN | 2015-04-14 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.57
-0.05 (-3.09%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
54.2K
Beta
1.94
Float Shares
3.65M
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.57% | -0.79% | -0.79% | -48.35% | -73.68% | -43.95% | -80.77% | -53.18% | -92.96% | -99.72% | -99.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
1.57
DCF (Unlevered)
1.05
-32.9%
DCF (Levered)
1.12
-28.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-93.93
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+46.2% ★ Q1'26: +34.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -1,935.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.20M
est: 1.30M (-7.6%)
|
835.0K
est: 1.00M (-16.5%)
|
335.0K
est: 300.0K (+11.7%)
|
7.91M
est: 6.23M (+27.1%)
|
12.63M
est: 10.60M (+19.2%)
|
5.17M
est: 5.89M (-12.2%)
|
6.07M
est: 6.24M (-2.6%)
|
7.30M
est: 6.90M (+5.8%)
|
7.81M
est: 6.90M (+13.1%)
|
—
est: 7.01M (-100.0%)
|
16.45M
16.45M – 16.45M
+134.9% YoY
|
27.52M
27.52M – 27.52M
+67.3% YoY
|
| EBITDA |
-15.39M
est: -1.21M (-1,168.4%)
|
-17.08M
est: -933.1K (-1,730.7%)
|
-17.23M
est: -279.9K (-6,055.0%)
|
-13.24M
est: -5.81M (-128.0%)
|
-9.65M
est: -9.89M (+2.5%)
|
-16.42M
est: -5.49M (-198.8%)
|
-18.79M
est: -5.82M (-222.9%)
|
-14.61M
est: -24.16M (+39.5%)
|
-7.04M
est: -4.00M (-75.8%)
|
-5.16M
est: -4.07M (-27.0%)
|
-9.55M
-9.55M – -9.55M
-134.9% YoY
|
-15.97M
-15.97M – -15.97M
-67.3% YoY
|
| EBIT |
-15.62M
est: -1.22M (-1,179.2%)
|
-17.33M
est: -939.2K (-1,745.4%)
|
-17.48M
est: -281.8K (-6,102.2%)
|
-13.42M
est: -5.85M (-129.6%)
|
-9.86M
est: -9.96M (+0.9%)
|
-16.59M
est: -5.53M (-200.0%)
|
-18.95M
est: -5.86M (-223.6%)
|
-14.74M
est: -25.29M (+41.7%)
|
-7.15M
est: -4.02M (-77.6%)
|
-5.16M
est: -4.08M (-26.4%)
|
-9.59M
-9.59M – -9.59M
-134.9% YoY
|
-16.05M
-16.05M – -16.05M
-67.3% YoY
|
| Net Income |
-26.17M
est: -2.01B (+98.7%)
|
-27.84M
est: -547.84M (+94.9%)
|
-18.06M
est: -686.63M (+97.4%)
|
-20.60M
est: -65.01M (+68.3%)
|
-19.31M
est: -59.90M (+67.8%)
|
-20.17M
est: -28.49M (+29.2%)
|
-18.84M
est: -21.04M (+10.5%)
|
-14.12M
est: -25.46M (+44.5%)
|
-9.56M
est: -16.44M (+41.8%)
|
-5.16M
est: -18.08M (+71.4%)
|
-8.18M
-8.18M – -8.18M
+54.7% YoY
|
2.12M
2.12M – 2.12M
+125.9% YoY
|
| SGA |
9.63M
est: 1.24M (+674.1%)
|
8.02M
est: 957.2K (+737.3%)
|
7.57M
est: 287.2K (+2,535.1%)
|
8.49M
est: 5.96M (+42.5%)
|
6.89M
est: 10.15M (-32.1%)
|
6.38M
est: 5.64M (+13.1%)
|
6.78M
est: 5.97M (+13.6%)
|
6.52M
est: 6.60M (-1.3%)
|
7.79M
est: 7.23M (+7.6%)
|
5.13M
est: 7.34M (-30.1%)
|
17.25M
17.25M – 17.25M
+134.9% YoY
|
28.85M
28.85M – 28.85M
+67.3% YoY
|
| EPS |
-646.91
est: -550.00 (-17.6%)
|
-375.87
est: -150.00 (-150.6%)
|
-186.42
est: -188.00 (+0.8%)
|
-24.37
est: -17.80 (-36.9%)
|
-19.83
est: -16.40 (-20.9%)
|
-8.63
est: -7.80 (-10.6%)
|
-5.43
est: -5.76 (+5.7%)
|
-3.87
est: -4.34 (+10.8%)
|
-2.62
est: -4.50 (+41.8%)
|
-1.41
est: -4.95 (+71.5%)
|
-2.24
-2.24 – -2.24
+54.7% YoY
|
0.58
0.58 – 0.58
+125.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-8.36M
OE per share TTM
-2.29
Owner's Yield
-183.10%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
37.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
4
Total invested
38.9K
Insider transactions (90d)
0
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Empery Asset Management, LP | 5.58M | 4.99% | — | 5.58M | — | — | PN | Delaware | 2020-01-15 | ↗ |
| 2 | Martin D. Hoe | 5.58M | 4.99% | — | 5.58M | — | — | IN | United States | 2020-01-15 | ↗ |
| 3 | Ryan M. Lane | 5.58M | 4.99% | — | 5.58M | — | — | IN | United States | 2020-01-15 | ↗ |
| 4 | Empery Tax Efficient II, LP | 4.89M | 9.99% | — | 4.89M | — | — | PN | Delaware | 2019-04-15 | ↗ |
| 5 | Daniel B. Asher | 3.34M | 5.60% | — | 3.34M | — | 3.21M | HC, IN | United States of America | 2022-02-11 | ↗ |
| 6 | Intracoastal Capital LLC | 3.34M | 5.60% | — | 3.34M | — | 3.21M | OO | Delaware | 2022-02-11 | ↗ |
| 7 | Mitchell P. Kopin | 3.34M | 5.60% | — | 3.34M | — | 3.21M | HC, IN | United States of America | 2022-02-11 | ↗ |
| 8 | CVI Investments, Inc. | 2.46M | 4.20% | — | 2.46M | — | 2.46M | CO | Cayman Islands | 2022-02-14 | ↗ |
| 9 | Heights Capital Management, Inc. | 2.46M | 4.20% | — | 2.46M | — | 2.46M | CO | Delaware | 2022-02-14 | ↗ |
| 10 | 13-3127734 | 2.45M | 4.36% | 2.22M | — | 2.45M | — | HC | Delaware | 2022-02-10 | ↗ |
| 11 | 26-0385758 | 2.45M | 4.36% | 2.22M | — | 2.45M | — | IA | Delaware | 2022-02-10 | ↗ |
| 12 | Empery Asset Master, Ltd. | 1.73M | 7.29% | — | 1.73M | — | — | OO | Cayman Islands | 2019-04-15 | ↗ |
| 13 | Sabby Volatility Warrant Master Fund, Ltd. | 1.64M | 5.30% | — | 1.64M | — | 1.64M | CO | Cayman Islands | 2020-07-24 | ↗ |
| 14 | Armistice Capital Master Fund Ltd. | 1.32M | 4.99% | — | 1.32M | — | 1.32M | CO | Delaware | 2020-04-24 | ↗ |
| 15 | Armistice Capital, LLC | 1.32M | 4.99% | — | 1.32M | — | 1.32M | IA, OO | Delaware | 2020-04-24 | ↗ |
| 16 | Steven Boyd | 1.32M | 4.99% | — | 1.32M | — | 1.32M | HC, IN | Delaware | 2020-04-24 | ↗ |
| 17 | Hal Mintz | 1.01M | 5.19% | — | 1.01M | — | 1.01M | IN | Cayman Islands | 2019-06-03 | ↗ |
| 18 | Michael Bigger | 630.8K | 3.10% | — | — | — | 630.8K | IN | Delaware | 2020-02-11 | ↗ |
| 19 | Bigger Capital Fund GP, LLC | 335.0K | 1.60% | — | — | — | 335.0K | OO | Delaware | 2020-02-11 | ↗ |
| 20 | Bigger Capital Fund, LP | 335.0K | 1.60% | — | — | — | 335.0K | PN | Delaware | 2020-02-11 | ↗ |
| 21 | District 2 Capital Fund LP | 295.8K | 1.50% | — | — | — | 295.8K | PN | Delaware | 2020-02-11 | ↗ |
| 22 | District 2 Capital LP | 295.8K | 1.50% | — | — | — | 295.8K | PN | Delaware | 2020-02-11 | ↗ |
| 23 | District 2 GP LLC | 295.8K | 1.50% | — | — | — | 295.8K | OO | Delaware | 2020-02-11 | ↗ |
| 24 | District 2 Holdings LLC | 295.8K | 1.50% | — | — | — | 295.8K | OO | Delaware | 2020-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
4
-10 vs prev Q
New positions
1
Closed positions
11
Increased
1
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 110.9K -3.5K (-3.0%) | 247.4K -308.6K (-55.5%) | 3.04% -0.095 pp | 0.00% 0.000 pp | USD5.98 -62.7% | 16 qtrs — |
| 2 | BLACKROCK, INC. | 55.3K +— (+0.0%) | 123.4K -145.5K (-54.1%) | 1.52% +0.000 pp | 0.00% +0.000 pp | USD2.18 +2.3% | 6 qtrs — |
| 3 | SBI SECURITIES CO., LTD. | 55.2K -4.1K (-6.9%) | 123.2K -165.2K (-57.3%) | 1.51% -0.112 pp | 0.00% -0.004 pp | USD6.97 -68.0% | 5 qtrs — |
| 4 | VANGUARD GROUP INC | 47.1K -2.3K (-4.7%) | 105.0K -135.6K (-56.4%) | 1.29% -0.064 pp | 0.00% +0.000 pp | USD5.34 -58.2% | 16 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 40.9K +— (+0.0%) | 91.3K -108.1K (-54.2%) | 1.12% +0.000 pp | 0.00% +0.000 pp | USD6.25 -64.3% | 16 qtrs — |
| 6 | DRW SECURITIES, LLC | 20.5K +20.5K (+100.0%) | 45.7K +45.7K (+100.0%) | 0.56% +0.561 pp | 0.00% +0.001 pp | USD2.23 +0.0% | 1 qtrs NEW |
| 7 | STATE STREET CORP | 13.9K +— (+0.0%) | 31.1K -36.8K (-54.2%) | 0.38% +0.000 pp | 0.00% +0.000 pp | USD6.83 -67.3% | 16 qtrs — |
| 8 | DIMENSIONAL FUND ADVISORS LP | 10.3K -454.0 (-4.2%) | 23.0K -29.5K (-56.1%) | 0.28% -0.012 pp | 0.00% +0.000 pp | USD4.86 -54.1% | 2 qtrs — |
| 9 | BANK OF AMERICA CORP /DE/ | 1.4K +1.3K (+4,036.4%) | 3.0K +2.9K (+1,790.7%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD2.24 -0.4% | 7 qtrs — |
| 10 | TOWER RESEARCH CAPITAL LLC (TRC) | 913.00 -523.0 (-36.4%) | 2.0K -4.9K (-70.8%) | 0.03% -0.014 pp | 0.00% 0.000 pp | USD4.49 -50.3% | 15 qtrs — |
| 11 | FLAGSHIP HARBOR ADVISORS, LLC | 80.00 +80.0 (+100.0%) | 178.00 +178.0 (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD2.23 +0.0% | 1 qtrs NEW |
| 12 | FARTHER FINANCE ADVISORS, LLC | 7.00 +— (+0.0%) | 16.00 -18.0 (-52.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.86 -54.1% | 2 qtrs — |
| 13 | ALLWORTH FINANCIAL LP | 3.00 +— (+0.0%) | 7.00 -8.0 (-53.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.67 -16.5% | 12 qtrs — |
| 14 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 1.00 -6.0 (-85.7%) | 2.00 -32.0 (-94.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.00 -44.3% | 2 qtrs — |
| 15 | BARCLAYS PLC | — -3.0 (-100.0%) | — -15.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 16 | UBS GROUP AG | — -129.0 (-100.0%) | — -627.0 (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 16 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 43.9K | 0.05% |
| 2 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.8K | 0.03% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.90 | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 10.72 | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 0.79 | 0.17% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 4.42 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.23 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 0.80 | 0.22% |
| 9 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 0.02 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 0.07 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
8.8K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+8,800
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-03 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 8,800 | 2.80 | 24.6K | 8,800 | — | ↗ |
| 2023-01-26 | Wasilewski Margaret | Officer | A-Award | A | Stock Option (Right to Buy) | 11,400 | 0.00 | — | 11,400 | — | ↗ |
| 2023-01-26 | Varadan Anand | Director | A-Award | A | Stock Option (Right to Buy) | 1,700 | 0.00 | — | 1,700 | — | ↗ |
| 2023-01-26 | Siegert Michelle | Officer | A-Award | A | Stock Option (Right to Buy) | 9,900 | 0.00 | — | 9,900 | — | ↗ |
| 2023-01-26 | Raad Teofilo David | Officer | A-Award | A | Stock Option (Right to Buy) | 34,900 | 0.00 | — | 34,900 | — | ↗ |
| 2023-01-26 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 2,436 | 0.00 | — | 2,436 | — | ↗ |
| 2023-01-26 | Cabell Christopher | Director | A-Award | A | Stock Option (Right to Buy) | 1,700 | 0.00 | — | 1,700 | — | ↗ |
| 2023-01-26 | Bazemore Todd | Director | A-Award | A | Stock Option (Right to Buy) | 1,700 | 0.00 | — | 1,700 | — | ↗ |
| 2023-01-26 | Batycky Richard P. | Director | A-Award | A | Stock Option (Right to Buy) | 1,700 | 0.00 | — | 1,700 | — | ↗ |
| 2022-04-18 | Ludlum Peter | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-01 | Wasilewski Margaret | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-27 | Varadan Anand | Director | A-Award | A | Stock Option (Right to Buy) | 22,100 | 0.37 | 8.2K | 22,100 | — | ↗ |
| 2022-01-27 | Siegert Michelle | Officer | A-Award | A | Stock Option (Right to Buy) | 184,300 | 0.37 | 68.2K | 184,300 | — | ↗ |
| 2022-01-27 | Raad Teofilo David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 0.37 | 277.6K | 750,000 | — | ↗ |
| 2022-01-27 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 36,833 | 0.37 | 13.6K | 36,833 | — | ↗ |
| 2022-01-27 | Cabell Christopher | Director | A-Award | A | Stock Option (Right to Buy) | 22,100 | 0.37 | 8.2K | 22,100 | — | ↗ |
| 2022-01-27 | Bazemore Todd | Director | A-Award | A | Stock Option (Right to Buy) | 22,100 | 0.37 | 8.2K | 22,100 | — | ↗ |
| 2022-01-27 | Batycky Richard P. | Director | A-Award | A | Stock Option (Right to Buy) | 22,100 | 0.37 | 8.2K | 22,100 | — | ↗ |
| 2021-07-26 | Varadan Anand | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-28 | Siegert Michelle | Officer | A-Award | A | Stock Option (Right to Buy) | 91,900 | 1.47 | 135.1K | 91,900 | — | ↗ |
| 2021-01-28 | Raad Teofilo David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 565,500 | 1.47 | 831.3K | 565,500 | — | ↗ |
| 2021-01-28 | Munshi Amit | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.47 | 22.1K | 15,000 | — | ↗ |
| 2021-01-28 | Iwicki Mark T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.47 | 22.1K | 15,000 | — | ↗ |
| 2021-01-28 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.47 | 36.8K | 25,000 | — | ↗ |
| 2021-01-28 | Cabell Christopher | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.47 | 22.1K | 15,000 | — | ↗ |
| 2021-01-28 | Bazemore Todd | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.47 | 22.1K | 15,000 | — | ↗ |
| 2021-01-28 | Batycky Richard P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.47 | 22.1K | 15,000 | — | ↗ |
| 2020-10-01 | Bazemore Todd | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-28 | GILLIS STEVEN | Director | D-Return | D | Stock Option (Right to Buy) | 111 | 110.00 | 12.2K | 0 | — | ↗ |
| 2020-06-23 | Cabell Christopher | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-21 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.28 | 19.2K | 15,000 | — | ↗ |
| 2020-04-02 | Raad Teofilo David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 1.28 | 12.8K | 10,000 | — | ↗ |
| 2020-04-02 | Munshi Amit | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 1.28 | 12.8K | 10,000 | — | ↗ |
| 2020-04-02 | Iwicki Mark T | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 1.28 | 12.8K | 10,000 | — | ↗ |
| 2020-04-02 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 1.28 | 12.8K | 10,000 | — | ↗ |
| 2020-04-02 | GILLIS STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 1.28 | 12.8K | 10,000 | — | ↗ |
| 2020-04-02 | Batycky Richard P. | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 1.28 | 12.8K | 10,000 | — | ↗ |
| 2020-01-09 | Siegert Michelle | Officer | A-Award | A | Stock Option (Right to Buy) | 64,500 | 1.54 | 99.3K | 64,500 | — | ↗ |
| 2020-01-09 | Raad Teofilo David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 471,460 | 1.54 | 726.0K | 471,460 | — | ↗ |
| 2020-01-09 | Munshi Amit | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.54 | 23.1K | 15,000 | — | ↗ |
| 2020-01-09 | Iwicki Mark T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.54 | 23.1K | 15,000 | — | ↗ |
| 2020-01-09 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.54 | 23.1K | 15,000 | — | ↗ |
| 2020-01-09 | GILLIS STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.54 | 23.1K | 15,000 | — | ↗ |
| 2020-01-09 | Batycky Richard P. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.54 | 46.2K | 30,000 | — | ↗ |
| 2019-11-13 | Siegert Michelle | Officer | — | D | Employee Stock Option (Right to Buy) | 1,320 | 28.00 | 37.0K | 0 | — | ↗ |
| 2019-11-01 | Batycky Richard P. | Director | — | D | Common Stock | 0 | 0.00 | — | 492 | — | ↗ |
| 2019-08-13 | Siegert Michelle | Officer | — | D | Employee Stock Option (Right to Buy) | 1,500 | 59.10 | 88.7K | 0 | — | ↗ |
| 2019-06-16 | Siegert Michelle | Officer | — | D | Employee Stock Option (Right to Buy) | 160 | 110.00 | 17.6K | 0 | — | ↗ |
| 2019-05-16 | Sherman Matthew L | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.06 | 15.9K | 15,000 | — | ↗ |
| 2019-05-16 | Raad Teofilo David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 320,000 | 1.06 | 339.2K | 320,000 | — | ↗ |
| 2019-05-16 | Munshi Amit | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.06 | 15.9K | 15,000 | — | ↗ |
| 2019-05-16 | MCGUIRE TERRANCE | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.06 | 15.9K | 15,000 | — | ↗ |
| 2019-05-16 | Iwicki Mark T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.06 | 15.9K | 15,000 | — | ↗ |
| 2019-05-16 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.06 | 15.9K | 15,000 | — | ↗ |
| 2019-05-16 | GILLIS STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.06 | 15.9K | 15,000 | — | ↗ |
| 2019-05-16 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 1.06 | 169.6K | 160,000 | — | ↗ |
| 2018-06-05 | Sherman Matthew L | Director | A-Award | A | Stock Option (Right to Buy) | 124,000 | 0.47 | 58.0K | 124,000 | — | ↗ |
| 2018-06-05 | Roach James M. | Officer | A-Award | A | Stock Option (Right to Buy) | 801,000 | 0.47 | 374.9K | 801,000 | — | ↗ |
| 2018-06-05 | Raad Teofilo David | Officer | A-Award | A | Stock Option (Right to Buy) | 741,000 | 0.47 | 346.8K | 741,000 | — | ↗ |
| 2018-06-05 | Munshi Amit | Director | A-Award | A | Stock Option (Right to Buy) | 124,000 | 0.47 | 58.0K | 124,000 | — | ↗ |
| 2018-06-05 | MCGUIRE TERRANCE | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 124,000 | 0.47 | 58.0K | 124,000 | — | ↗ |
| 2018-06-05 | Iwicki Mark T | Director | A-Award | A | Stock Option (Right to Buy) | 155,000 | 0.47 | 72.5K | 155,000 | — | ↗ |
| 2018-06-05 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 124,000 | 0.47 | 58.0K | 124,000 | — | ↗ |
| 2018-06-05 | Hava David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 795,000 | 0.47 | 372.1K | 795,000 | — | ↗ |
| 2018-06-05 | GILLIS STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 124,000 | 0.47 | 58.0K | 124,000 | — | ↗ |
| 2018-06-05 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 850,000 | 0.47 | 397.8K | 850,000 | — | ↗ |
| 2018-06-05 | Clarke Robert W. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,000,000 | 0.47 | 936.0K | 2,000,000 | — | ↗ |
| 2018-04-03 | Sherman Matthew L | Director | P-Purchase | A | Series A Warrant (right to buy) | 20,000 | 0.65 | 13.0K | 20,000 | — | ↗ |
| 2018-04-03 | MCGUIRE TERRANCE | Director / 10% Owner | P-Purchase | A | Series A Warrant (right to buy) | 5,275 | 0.65 | 3.4K | 5,275 | — | ↗ |
| 2018-04-03 | Iwicki Mark T | Director | P-Purchase | A | Series A Warrant (right to buy) | 307,000 | 0.65 | 199.6K | 307,000 | — | ↗ |
| 2018-04-03 | GILLIS STEVEN | Director | P-Purchase | A | Common Stock | 1,150,000 | 0.65 | 747.5K | 3,436,456 | — | ↗ |
| 2018-04-03 | Arch Venture Fund VII LP | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-03 | Roach James M. | Officer | A-Award | A | Stock Option (Right to Buy) | 360,000 | 1.57 | 565.2K | 360,000 | — | ↗ |
| 2017-06-13 | Munshi Amit | Director | A-Award | A | Stock Option (Right to Buy) | 8,800 | 2.39 | 21.0K | 8,800 | — | ↗ |
| 2017-05-01 | Raad Teofilo David | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-03-22 | Hava David L. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,263 | 2.21 | 5.0K | 1,292 | — | ↗ |
| 2017-03-22 | Clarke Robert W. | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,525 | 2.21 | 10.0K | 2,665 | — | ↗ |
| 2017-03-20 | Sherman Matthew L | Director | A-Award | A | Stock Option (Right to Buy) | 4,400 | 2.78 | 12.2K | 4,400 | — | ↗ |
| 2017-03-20 | MCGUIRE TERRANCE | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 4,400 | 2.78 | 12.2K | 4,400 | — | ↗ |
| 2017-03-20 | Iwicki Mark T | Director | A-Award | A | Stock Option (Right to Buy) | 4,400 | 2.78 | 12.2K | 4,400 | — | ↗ |
| 2017-03-20 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 4,400 | 2.78 | 12.2K | 4,400 | — | ↗ |
| 2017-03-20 | Hava David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,100 | 2.78 | 208.8K | 75,100 | — | ↗ |
| 2017-03-20 | GILLIS STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 4,400 | 2.78 | 12.2K | 4,400 | — | ↗ |
| 2017-03-20 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,100 | 2.78 | 208.8K | 75,100 | — | ↗ |
| 2017-03-20 | Clarke Robert W. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 159,000 | 2.78 | 442.0K | 159,000 | — | ↗ |
| 2016-09-29 | Sherman Matthew L | Director | A-Award | A | Stock Option (Right to Buy) | 8,800 | 1.55 | 13.6K | 8,800 | — | ↗ |
| 2016-02-03 | ROCKLAGE SCOTT M | Director | A-Award | A | Stock Option (Right to Buy) | 8,800 | 2.80 | 24.6K | 8,800 | — | ↗ |
| 2016-02-03 | MCGUIRE TERRANCE | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 8,800 | 2.80 | 24.6K | 8,800 | — | ↗ |
| 2016-02-03 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 8,800 | 2.80 | 24.6K | 8,800 | — | ↗ |
| 2016-02-03 | Hava David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 150,200 | 2.80 | 420.6K | 150,200 | — | ↗ |
| 2016-02-03 | Graves Kurt | Director | A-Award | A | Stock Option (Right to Buy) | 8,800 | 2.80 | 24.6K | 8,800 | — | ↗ |
| 2016-02-03 | GILLIS STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 8,800 | 2.80 | 24.6K | 8,800 | — | ↗ |
| 2016-02-03 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 150,200 | 2.80 | 420.6K | 150,200 | — | ↗ |
| 2016-02-03 | Clarke Robert W. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 318,000 | 2.80 | 890.4K | 318,000 | — | ↗ |
| 2015-12-08 | Iwicki Mark T | Director | A-Award | A | Stock Option (Right to Buy) | 73,481 | 4.75 | 349.0K | 73,481 | — | ↗ |
| 2015-12-08 | Graves Kurt | Director | A-Award | A | Stock Option (Right to Buy) | 18,818 | 4.75 | 89.4K | 18,818 | — | ↗ |
| 2015-11-01 | Siegert Michelle | Officer | — | D | Employee Stock Option (Right to Buy) | 445 | 20.30 | 9.0K | 0 | — | ↗ |
| 2015-10-01 | Siegert Michelle | Officer | — | D | Employee Stock Option (Right to Buy) | 315 | 18.80 | 5.9K | 0 | — | ↗ |
| 2015-06-24 | ROCKLAGE SCOTT M | Director | A-Award | A | Stock Option (Right to Buy) | 1,108 | 11.00 | 12.2K | 1,108 | — | ↗ |
| 2015-06-24 | MCGUIRE TERRANCE | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 1,108 | 11.00 | 12.2K | 1,108 | — | ↗ |
| 2015-06-24 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 2,217 | 11.00 | 24.4K | 2,217 | — | ↗ |
| 2015-06-24 | Hava David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 20,508 | 11.00 | 225.6K | 20,508 | — | ↗ |
| 2015-06-24 | GILLIS STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 1,108 | 11.00 | 12.2K | 1,108 | — | ↗ |
| 2015-06-24 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 235,224 | 11.00 | 2.59M | 235,224 | — | ↗ |
| 2015-06-24 | Clarke Robert W. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 44,341 | 11.00 | 487.8K | 44,341 | — | ↗ |
| 2015-06-17 | Oculus Innovative Sciences, Inc. | 10% Owner | S-Sale | D | Common Stock $0.0001 per value share | 922,500 | 2.75 | 2.54M | 0 | — | ↗ |
| 2015-06-16 | ROCKLAGE SCOTT M | Director | A-Award | A | Stock Option (Right to Buy) | 17,710 | 11.80 | 209.0K | 17,710 | — | ↗ |
| 2015-06-16 | Oculus Innovative Sciences, Inc. | 10% Owner | S-Sale | D | Common Stock $0.0001 per value share | 727,500 | 2.75 | 2.00M | 922,500 | — | ↗ |
| 2015-06-16 | Maki David | Director | P-Purchase | A | Common Stock | 36,375 | 6.88 | 250.1K | 218,194 | — | ↗ |
| 2015-06-16 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 35,419 | 11.80 | 417.9K | 35,419 | — | ↗ |
| 2015-06-16 | Hava David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 267,129 | 11.80 | 3.15M | 267,129 | — | ↗ |
| 2015-06-16 | Graves Kurt | Director | A-Award | A | Stock Option (Right to Buy) | 10,969 | 11.80 | 129.4K | 10,969 | — | ↗ |
| 2015-06-16 | GILLIS STEVEN | Director | P-Purchase | A | Common Stock | 72,750 | 6.88 | 500.2K | 2,286,456 | — | ↗ |
| 2015-06-16 | Clarke Robert W. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 407,907 | 11.80 | 4.81M | 407,907 | — | ↗ |
| 2015-06-15 | ROCKLAGE SCOTT M | Director | A-Award | A | Warrants to Purchase Common Stock | 52,784 | 7.56 | 399.2K | 52,784 | — | ↗ |
| 2015-06-15 | Maki David | Director | A-Award | A | Stock Option (Right to Buy) | 1,186 | 2.20 | 2.6K | 1,186 | — | ↗ |
| 2015-06-15 | MCGUIRE TERRANCE | Director / 10% Owner | A-Award | A | Warrants to Purchase Common Stock | 5,365 | 7.56 | 40.6K | 5,365 | — | ↗ |
| 2015-06-15 | Higgins Michael J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-06-15 | Hava David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 14,819 | 1.88 | 27.9K | 14,819 | — | ↗ |
| 2015-06-15 | Graves Kurt | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-06-15 | GILLIS STEVEN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-06-15 | Clarke Robert W. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 7,190 | 2.20 | 15.8K | 7,190 | — | ↗ |
| 2015-04-30 | French Gregory M | Director | A-Award | A | Stock option (right to buy) | 5,000 | 3.35 | 16.8K | 5,000 | — | ↗ |
| 2015-04-30 | Conley Richard K | Director | A-Award | A | Stock option (right to buy) | 5,000 | 3.35 | 16.8K | 5,000 | — | ↗ |
| 2015-04-30 | Akao Akihisa | Director | A-Award | A | Stock option (right to buy) | 5,000 | 3.35 | 16.8K | 5,000 | — | ↗ |
| 2015-03-23 | Oculus Innovative Sciences, Inc. | 10% Owner | S-Sale | D | Common Stock, $0.0001 par value per share | 350,000 | 2.75 | 962.5K | 1,650,000 | — | ↗ |
| 2015-02-27 | Akao Akihisa | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-08-23 | Siegert Michelle | Officer | — | D | Employee Stock Option (Right to Buy) | 119 | 22.10 | 2.6K | 0 | — | ↗ |
| 2014-05-12 | Harish Sameer | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 6.37 | 668.9K | 105,000 | — | ↗ |
| 2014-05-12 | French Gregory M | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 6.37 | 63.7K | 10,000 | — | ↗ |
| 2014-05-12 | Conley Richard K | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 6.37 | 63.7K | 10,000 | — | ↗ |
| 2014-05-12 | Alimi Hojabr | Director / Officer | A-Award | A | Stock Option (right to buy) | 159,500 | 6.37 | 1.02M | 159,500 | — | ↗ |
| 2014-05-11 | Harish Sameer | Officer | A-Award | A | Common Stock | 74,600 | 0.00 | — | 74,600 | — | ↗ |
| 2014-05-11 | French Gregory M | Director | A-Award | A | Common Stock | 58,000 | 0.00 | — | 58,000 | — | ↗ |
| 2014-05-11 | Conley Richard K | Director | A-Award | A | Common Stock | 58,000 | 0.00 | — | 58,000 | — | ↗ |
| 2014-05-11 | Alimi Hojabr | Director / Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2014-03-26 | Oculus Innovative Sciences, Inc. | 10% Owner | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 2,000,000 | — | ↗ |
| 2014-03-21 | Harish Sameer | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-03-21 | French Gregory M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-03-21 | Conley Richard K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-03-21 | Alimi Hojabr | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
3.65M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Teofilo Raad (former Chief Executive Officer) | 567.3K | — | — | 114.2K | — | 10.4K | 691.9K | 16.50% | ↗ |
| 2 | 2023 | Peter Ludlum (Interim Chief Financial Officer) | — | — | — | — | — | 510.2K | 510.2K | 0.00% | ↗ |
| 3 | 2023 | Margaret Wasilewski, M.D. (former Chief Medical Officer) | 461.9K | — | — | 37.3K | — | 10.4K | 509.6K | 7.32% | ↗ |
| 4 | 2022 | Teofilo Raad (Chief Executive Officer) | 525.3K | — | — | 234.4K | 237.0K | 10.4K | 1.01M | 23.27% | ↗ |
| 5 | 2022 | Teofilo Raad (former Chief Executive Officer) | 525.3K | — | — | 234.4K | 237.0K | 10.4K | 1.01M | 23.27% | ↗ |
| 6 | 2022 | Margaret Wasilewski, M.D. (former Chief Medical Officer) | 368.3K | — | — | 101.9K | 133.8K | 10.1K | 614.1K | 16.59% | ↗ |
| 7 | 2022 | Margaret Wasilewski, M.D. (Chief Medical Officer) | 368.3K | — | — | 101.9K | 133.8K | 10.1K | 614.1K | 16.59% | ↗ |
| 8 | 2022 | Michelle S. Siegert (former Vice President, Finance) | 299.7K | 43.0K | — | 57.6K | 81.1K | 10.4K | 491.9K | 11.71% | ↗ |
| 9 | 2022 | Michelle S. Siegert (Vice President, Finance) | 299.7K | 43.0K | — | 57.6K | 81.1K | 10.4K | 491.9K | 11.71% | ↗ |
| 10 | 2022 | Peter Ludlum (Interim Chief Financial Officer) | — | — | — | — | — | 398.6K | 398.6K | 0.00% | ↗ |
| 11 | 2021 | Teofilo Raad (Chief Executive Officer) | 479.7K | — | — | 668.4K | 223.1K | 10.7K | 1.38M | 48.37% | ↗ |
| 12 | 2021 | Michelle S. Siegert (Vice President, Finance) | 286.9K | 2.0K | — | 108.6K | 72.0K | 10.7K | 480.3K | 22.61% | ↗ |
| 13 | 2020 | Teofilo Raad (Chief Executive Officer) | 463.5K | — | — | 1.47M | 231.8K | 7.7K | 2.17M | 67.66% | ↗ |
| 14 | 2020 | Teofilo Raad (Chief Executive Officer; Former Chief Business Officer) | 463.5K | — | — | 1.47M | 231.8K | 7.7K | 2.17M | 67.66% | ↗ |
| 15 | 2020 | Michelle S. Siegert (Vice President, Finance) | 277.2K | 22.5K | — | 255.8K | 83.2K | 7.5K | 646.1K | 39.58% | ↗ |
| 16 | 2019 | Teofilo Raad (Chief Executive Officer; Former Chief Business Officer) | 411.3K | — | — | 223.7K | 182.3K | 6.1K | 823.4K | 27.17% | ↗ |
| 17 | 2019 | Robert W. Clarke, Ph.D (Former Chief Executive Officer) | 176.6K | 32.9K | — | — | — | 310.9K | 520.4K | 0.00% | ↗ |
| 18 | 2019 | William Duke, Jr. (Former Chief Financial Officer) | 347.4K | — | — | 111.8K | — | 6.1K | 465.3K | 24.04% | ↗ |
| 19 | 2019 | Michelle S. Siegert (Vice President, Finance) | 220.2K | 22.5K | — | 17.5K | 54.0K | 6.1K | 320.4K | 5.48% | ↗ |
| 20 | 2018 | Robert W. Clarke, Ph.D (Former Chief Executive Officer) | 434.1K | 176.5K | — | 634.0K | — | 6.0K | 1.25M | 50.70% | ↗ |
| 21 | 2018 | Robert W. Clarke, Ph.D (Former Chief Executive Officer ) | 434.1K | — | — | 634.0K | 176.5K | 6.0K | 1.25M | 50.70% | ↗ |
| 22 | 2018 | William Duke, Jr. (Former Chief Financial Officer) | 338.2K | 120.9K | — | 269.5K | — | 6.0K | 734.6K | 36.68% | ↗ |
| 23 | 2018 | William Duke, Jr. (Chief Financial Officer) | 338.2K | — | — | 269.5K | 120.9K | 6.0K | 734.6K | 36.68% | ↗ |
| 24 | 2018 | Teofilo Raad (Chief Executive Officer; Former Chief Business Officer) | 345.1K | 121.4K | — | 234.9K | — | 6.0K | 707.5K | 33.20% | ↗ |
| 25 | 2018 | Michelle S. Siegert (Vice President, Finance) | 213.9K | 52.5K | — | 57.9K | — | 6.0K | 330.4K | 17.54% | ↗ |
| 26 | 2017 | Teofilo Raad (Chief Business Officer) | 215.8K | 79.9K | — | 594.6K | — | 4.7K | 894.9K | 66.44% | ↗ |
| 27 | 2017 | Robert W. Clarke, Ph.D. (Chief Executive Officer) | 407.9K | 165.0K | — | 305.0K | — | 5.8K | 883.6K | 34.52% | ↗ |
| 28 | 2017 | Teofilo Raad (Chief Executive Officer; Former Chief Business Officer) | 215.8K | — | — | 594.6K | 39.9K | 4.7K | 855.0K | 69.55% | ↗ |
| 29 | 2017 | Robert W. Clarke, Ph.D (Former Chief Executive Officer ) | 407.9K | — | — | 305.0K | 82.5K | 5.8K | 801.1K | 38.07% | ↗ |
| 30 | 2017 | James M. Roach, M.D. (Chief Medical Officer) | 51.3K | 172.0K | — | 377.8K | — | 1.1K | 602.1K | 62.74% | ↗ |
| 31 | 2017 | William Duke, Jr. (Chief Financial Officer) | 313.3K | — | — | 144.0K | 55.4K | 5.8K | 518.6K | 27.77% | ↗ |
| 32 | 2016 | Robert W. Clarke, Ph.D. (Chief Executive Officer) | 396.9K | 159.4K | — | 566.5K | — | 5.7K | 1.13M | 50.20% | ↗ |
| 33 | 2016 | William E. Duke, Jr. (Chief Financial Officer) | 305.4K | 53.6K | — | 267.6K | — | 5.7K | 632.3K | 42.32% | ↗ |
| 34 | 2016 | David L. Hava, Ph.D. (Chief Scientific Officer) | 293.8K | 44.2K | — | 267.6K | — | 5.7K | 611.3K | 43.77% | ↗ |
| 35 | 2016 | Sameer Harish (Former Chief Financial Officer) | 1.1K | — | — | — | — | — | 1.1K | 0.00% | ↗ |
| 36 | 2016 | Hojabr Alimi (Former Chief Executive Officer and Former Chief Science Officer) | 1.1K | — | — | — | — | — | 1.1K | 0.00% | ↗ |
| 37 | 2015 | Robert W. Clarke, Ph.D. (Chief Executive Officer) | 220.6K | 115.5K | — | 5.10M | — | 208.00 | 5.43M | 93.81% | ↗ |
| 38 | 2015 | Hojabr Alimi (Former Chief Executive Officer and Former Chief Science Officer) | 80.0K | — | 3.13M | — | — | 589.2K | 3.79M | 82.36% | ↗ |
| 39 | 2015 | David L. Hava, Ph.D. (Chief Scientific Officer) | 163.3K | 64.1K | — | 2.29M | — | 2.4K | 2.52M | 90.89% | ↗ |
| 40 | 2015 | William E. Duke, Jr. (Chief Financial Officer) | 160.4K | 91.3K | — | 1.76M | — | 3.4K | 2.01M | 87.32% | ↗ |
| 41 | 2015 | Sameer Harish (Former Chief Financial Officer) | 46.9K | — | 1.04M | — | — | 364.2K | 1.45M | 71.62% | ↗ |
| 42 | 2014 | Hojabr Alimi (Former Chief Executive Officer and Former Chief Science Officer) | 375.0K | — | 939.0K | 764.0K | — | 50.9K | 2.13M | 80.00% | ↗ |
| 43 | 2014 | Sameer Harish (Former Chief Financial Officer) | 225.0K | — | 563.9K | 95.8K | — | 8.0K | 892.6K | 73.90% | ↗ |
| 44 | 2014 | Hojabr Alimi Chief Executive Officer and Chief Science Officer | 375.0K | 158.0K | — | — | — | 51.9K | 584.9K | 0.00% | ↗ |
| 45 | 2014 | Sameer Harish Chief Financial Officer | 225.0K | — | — | — | — | — | 225.0K | 0.00% | ↗ |
| 46 | 2013 | Hojabr Alimi Chief Executive Officer and Chief Science Officer | 59.1K | — | — | — | — | 519.00 | 59.7K | 0.00% | ↗ |
| 47 | 2013 | Sameer Harish Chief Financial Officer | 35.5K | — | — | — | — | — | 35.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter Ludlum | Interim Chief Executive Officer & Interim Chief Financial Officer | 715.2K | male |
| Alexander Klibanov | Founder | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PULM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
